<DOC>
	<DOCNO>NCT02893189</DOCNO>
	<brief_summary>Eligible patient receive escalate dos 4G7-CARD T-cells parallel clinical standard care unmanipulated donor lymphocyte . There 3 intra-patient dose level plan . Patients follow regularly interventional phase study 12 month post-final 4G7-CARD T-cell infusion . Thereafter patient follow annually year 2 3 .</brief_summary>
	<brief_title>CAR19 Donor Lymphocytes Relapsed CD19+ Malignancies Following Allogeneic Transplantation</brief_title>
	<detailed_description>Patients receive escalate dos 4G7-CARD T-cells without pre-conditioning , parallel clinical standard care unmanipulated donor lymphocyte . Intra-patient dose escalation proceed interval less 8 week , dependent development toxicity evidence efficacy confirmation Trial Management Group . Three dose cohort level plan , dose accord total CD3+ T- cell dose correlate toxicity unmanipualated donor lymphocyte setting : - Dose Level 1 : 1x10^6 CD3+ T-cells/kg ( start dose patient ) - Dose Level 2 : 3x10^6 CD3+ T-cells/kg - Dose Level 3 : 1x10^7 CD3+ T-cells/kg The inter-patient dosing first 3 patient least 28 day , follow TMG confirmation . After first 3 patient receive dose level 1 Independent Data Management Committee advise whether inter-patient dose interval subsequent patient shorten . Patients follow regularly interventional phase study 12 month post-final 4G7-CARD T-cell infusion . During long term follow phase study ( year 2-3 post-final 4G7-CARD T-cell infusion ) patient followed-up annually overall survival , disease status safety . All patient enter long term follow 3 year post-final 4G7-CARD T-cell infusion .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>1 . Age 1670 year 2 . Confirmed diagnosis CD19+ malignancy relapse follow allogeneic transplantation 3 . Agreement pregnancy test , use adequate contraception 12 month postfinal 4G7CARD Tcell infusion 4 . Karnofsky performance status &gt; 60 5 . Written inform consent 1 . Women pregnant lactate 2 . Prior history ischaemic heart disease , dysrhythmias , abnormal ECG ( LBBB ) , Multi Gated Acquisition Scan ( MUGA ) leave ventricular ejection fraction ( LVEF &lt; 40 % ) ( perform ) 3 . Known involvement central nervous system cerebral vascular accident within prior 3 month 4 . Patients receive corticosteroid dose &gt; 10mg prednisolone per day ( equivalent ) 5 . Active graft versus host disease require immunosuppression 6 . Use rituximab within last 2 month prior ATIMP infusion 7 . Known allergy albumin dimethyl sulfoxide ( DMSO ) 8 . Patients experience significant neurotoxicity follow blinatumomab treatment</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>CD19+</keyword>
	<keyword>allogeneic transplant</keyword>
	<keyword>relapse</keyword>
</DOC>